Lung Cancer
Conditions
Brief summary
This is a West Philadelphia based community project to improve adherence to lung cancer screening. The overall objective of this project is to demonstrate the impact of a community support program (CSP) on improve adherence to LCS follow-up guidelines in an urban environment. The study will target individuals in the Penn Medicine healthcare system residing in Philadelphia with an upcoming or missed follow-up screening or orders placed but who have not yet scheduled their screenings by offering free transportation coordination to and from the appointment. The study team will also offer to connect those with placed but unscheduled low dose CT orders to connect with Penn Medicine's scheduling staff.
Interventions
BEHAVIORALTransportation
Participants with ordered low dose CT and participants with scheduled low dose CT are offered free transportation to and from appointment. Participants with ordered low dose CT are also offered assistance in connecting with scheduling staff.
BEHAVIORALScheduling
Participants with ordered low dose CT are offered assistance in connecting with scheduling staff.
Sponsors
Abramson Cancer Center at Penn Medicine
University of Pennsylvania
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
HEALTH_SERVICES_RESEARCH
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 89 Years
Healthy volunteers
Yes
Inclusion criteria
* Upcoming or missed low dose CT for lung cancer screening * Philadelphia resident
Exclusion criteria
* Lives outside Philadelphia city limits
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Scheduled Lung Cancer Screening Appointments Attended by Participants | 12 months | The Primary Outcome measures appointment attendance across three groups: West Philadelphia CSP Participants (eligible West Philadelphia residents who opted into the CSP), West Philadelphia Non CSP Participants (eligible West Philadelphia residents who did not opt into the CSP), and Southwest Philadelphia Residents (patients who did not receive an option to participate in the CSP). |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| CSP Enrollment | 12 months | The Secondary outcome is a measurement of the how many eligible participants (West Philadelphia residents) chose to opt into the CSP (as opposed to eligible participants who did not). |
Countries
United States
Contacts
PRINCIPAL_INVESTIGATORFarouk Dako, MD
farouk.dako@pennmedicine.upenn.edu
Baseline characteristics
| Characteristic | — |
|---|---|
| Age, Categorical <=18 years | 0 Participants |
| Age, Categorical >=65 years | 0 Participants |
| Age, Categorical Between 18 and 65 years | 252 Participants |
| Ethnicity (NIH/OMB) Hispanic or Latino | 1 Participants |
| Ethnicity (NIH/OMB) Not Hispanic or Latino | 111 Participants |
| Ethnicity (NIH/OMB) Unknown or Not Reported | 18 Participants |
| Race (NIH/OMB) American Indian or Alaska Native | 2 Participants |
| Race (NIH/OMB) Asian | 0 Participants |
| Race (NIH/OMB) Black or African American | 92 Participants |
| Race (NIH/OMB) More than one race | 0 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 8 Participants |
| Race (NIH/OMB) White | 2 Participants |
| Region of Enrollment United States | 113 participants |
| Scheduled Lung Cancer Screening | 113 Participants |
| Sex/Gender, Customized Female | 64 Participants |
| Sex/Gender, Customized Male | 39 Participants |
| Sex/Gender, Customized Not Reported | 0 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk |
|---|---|---|---|
| deaths Total, all-cause mortality | 0 / 0 | 0 / 0 | 0 / 0 |
| other Total, other adverse events | 0 / 0 | 0 / 0 | 0 / 0 |
| serious Total, serious adverse events | 0 / 0 | 0 / 0 | 0 / 0 |
Outcome results
None listed